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Objective: To investigate the relationship between efﬁcacy of a bisphosphonate, pain and extent of joint
damage in the monosodium iodoacetate (MIA) model of painful degenerative joint disease.
Methods: Zoledronate treatment was initiated prior to and at various times following model induction,
including late time points representing advanced disease. Radiographic and histological structural
parameters were correlated with pain as measured by weight bearing.
Results: Intraarticular (IA) MIA resulted in a progressive loss of bone mineral density (BMD) and chon-
drocytes, thinning of cartilage, loss of proteoglycan, resorption of calciﬁed cartilage and subchondral
bone, as well as pain. This was completely prevented by pre-emptive chronic zoledronate treatment with
joint sections being histologically indistinguishable from saline-injected controls. When initiation of
treatment was delayed efﬁcacy was reduced. In animals with advanced joint degeneration, treatment
partially restored BMD and had a signiﬁcant, but limited, effect on pain. We conﬁrmed these radiographic
and behavioral ﬁndings in the medial meniscal tear model. To understand the mechanism-of-action of
zoledronate we investigated an early time point 4 days post-model induction when chondrocytes were
histologically viable, with minor loss of proteoglycan and generalized synovitis. Osteoclast-mediated
resorption of the calciﬁed cartilage was observed and was prevented by two doses of zoledronate.
Conclusion: Subchondral bone remodeling plays an important role in nociception and the pathobiology of
the MIA model with osteoclasts being implicated in both bone and cartilage resorption. Inhibition of
osteoclastic activity when initiated early leads to improved efﬁcacy.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Osteoarthritis (OA) is a degenerative joint disease characterized
by progressive loss of cartilage, changes in subchondral bone,
inactivity-related stiffness and chronic pain1e4. OA is commonly
idiopathic, however it can be precipitated and its progression
accelerated by joint injury5,6.
OA is increasingly recognized as a disease of the entire joint with
changes noted in the cartilage, meniscus, synovium and sub-
chondral bone. The latter displays decreased bone mineral content
and quality, increased turnover and resorption, cyst formation and
development of marginal osteophytes3,7,8. Bone changes occur
early9 and persist to late-stage OA10. Bone alterations are not
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patients with progressive OA have high subchondral bone turn-
over2, cartilage loss in regions of subchondral bone attrition13 and
pain which correlates with exposure of the subchondral bone
plate14. However, the exact relationship between changes in the
subchondral bone and other osteoarthritic events has yet to be fully
elucidated. In addition, although pain is an important presenting
feature of OA15, the speciﬁc source and molecular events respon-
sible for pain originating from the osteoarthritic joint are not
completely understood.
Bisphosphonates inhibit bone resorption by osteoclasts, and are
used to treat osteoporosis16. While bisphosphonates have shown
promise in animal models of OA17e19, clinical results have been
mixed. In controlled clinical trials, patients realized a beneﬁt from
bisphosphonates in terms of pain, function, and radiographic joint
space narrowing (JSN)20e22. In contrast, a subsequent larger trial of
risedronate did not demonstrate an improvement on JSN or on theublished by Elsevier Ltd. All rights reserved.
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of a biomarker of collagen degradation was noted, and in patients
with rapid progression of JSN, vertebral trabecular structure was
retained1,2,20. Importantly, inclusion criteria for patients in these
trials included presence of at least one osteophyte, substantial JSN,
signiﬁcant knee pain for most days during 1 month of the 3-month
pretrial period1 and existing OA as diagnosed according to the
clinical radiological criteria for the American College of Rheuma-
tology2. While the extent of OAwas described as mild-to-moderate,
these inclusion criteria may deﬁne a patient population with rela-
tively advanced disease. In addition, the radiographic JSN was very
heterogeneous and the placebo group did not progress, making it
impossible to ascertain the true beneﬁt of therapy with this tech-
nique and time period. In animal studies, zoledronate inhibits
cartilage degeneration following chymopapain-induced matrix
damage in rabbits19 and reduces markers of bone turnover in dogs% Weight on ipsilateral hindlimb ¼ weight on ipsilateral hindlimbðweight on ipsilateral hindlimbþweight on contralateral hindlimbÞ  100following transection of the cranial cruciate ligament17. The related
bisphosphonate, alendronate, also reduces cartilage degeneration
and prevents osteophytes induced by anterior cruciate
ligament (ACL) transection in rats18. Importantly, in these studies,
dosing was started prior to OA induction in a pre-emptive treat-
ment regime.
While likely that the efﬁcacy of bisphosphonates in OA depends
upon the disease stage when treatment is initiated, a correlation in
animal models with either modulation of structural changes or alle-
viationof painhas not been conducted.Weused the third-generation
bisphosphonate, zoledronate, to investigate this relationship in the
context of a well-characterized model of painful joint degeneration:
intraarticular (IA) administration of the glycolysis inhibitor, mono-
sodium iodoacetic acid (MIA)23e27 to youngadult rats. In addition,we
conﬁrmed the radiographic and behavioral ﬁndings in the medial
meniscal tear surgical model of OA. We initiated treatment at
different times followingmodel induction, including late time points
representative of advanced disease, and correlated radiographic and
histological structural parameters with pain. Early in the MIAmodel,
chondrocytes were alive and the pathology appeared from foci of
osteoclastic resorption from moving bone through the cartilage.
Zoledronate treatment signiﬁcantly attenuated both structural
changes and pain. Overall, our data implicate subchondral bone, and
speciﬁcally osteoclastic activity, in bone and cartilage resorption and
degeneration, in addition to nociception in OA.
Materials and methods
Animals
Male SpragueeDawley rats, 8 weeks, z250 g (Harlan; Indian-
apolis, IN) were group housed on a 12-h light/dark cycle with food
and water available ad libitum. Animals were 400e450 g at time of
sacriﬁce (6 weeks post-model induction); a total of 195 animals
were used for these studies (110 animals were used for studies
presented as Supplementary data). All procedures were approved
by the Wyeth Institutional Animal Care and Use Committee.
MIA model
Animals were anesthetized (3% isoﬂurane, Baxter Healthcare
Corp., Deerﬁeld, IL), the left knee shaved and a 27G 0.5-inch needleinserted through the patellar tendon into the IA space. Rats
received a single injection of 0.3,1.0, or 3.0 mgMIA (Sigma; St Louis,
MO) in a total volume of 20 ml saline (10 animals/group). Control/
sham rats received an IA injection of saline (20 ml).Behavioral testing
Hind limb weight bearing was assessed using a Linton Incapa-
citance Meter (IITC Life Sciences; Woodland Hills CA) as previously
described24,28,29. Rats were randomized, acclimatized to the testing
apparatus and three consecutive 4-s readings taken. Testing was
performed, by an experimenter blinded to model/treatment, on
days that rats were not dosed with zoledronate. The percent weight
borne on the ipsilateral hind limb was determined using the
following formula:Pharmacological testing
Zoledronate (disodium tetrahydrate) was obtained from TRC
(Toronto, Canada) and dissolved in sterile 0.01 M phosphate buff-
ered saline (PBS) for subcutaneous (s.c.) administration (volume:
1 ml/kg). As shown in the Scheme 1, ﬁve different dosing regimes
were used allowing investigation of both duration of treatment and
time treatment was initiated.
1. Pre-emptive Chronic (10, 30 or 100 mg/kg, every third day from
day 1 to 21).
2. Early Sub-chronic (100 mg/kg, every third day from day 14 to
21).
3. Early Chronic (100 mg/kg, every third day from day 14 to 35).
4. Delayed Chronic (100 mg/kg, every third day from day 21 to 35).
5. Curative Sub-chronic (100 mg/kg, every third day from day 28 to
35).
Samples were taken for histological analysis from the pre-
emptive chronic group on day 5 and from the pre-emptive chronic
and early sub-chronic groups on day 22; weight bearing and bone
densitometry analysis was performed weekly.
Lidocaine (HCl) 2% was obtained from Hospira, Inc. (Lake Forest,
IL). Three weeks post-MIA, rats received 50 ml of lidocaine or saline
intraarticularly and hind limb weight bearing was assessed 30 min
later.
Radiological analysis
High-resolution radiographs were taken at 26 kV with a 10 s
exposure using a Faxitron MX-20 radiography system (Faxitron
X-ray Corp., Wheeling, IL): bone mineral density (BMD) was
determined using dual energy X-ray absorptiometry (PIXImus
Densitometer; GE Lunar, Madison, WI) as previously described24,29.
The region of interest included the tibial plus femoral area between
the epiphysial growth plate and articular cartilage. The instrument
was calibrated before sessions using a Phantom of known BMD.
Histological analysis and OA severity scoring
Animals were sacriﬁced, and 3e5 knees/group trimmed, ﬁxed
in 10% neutral buffered-formalin, and decalciﬁed in formic acid for
Scheme 1.
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embedded in the same parafﬁn block. Three sections were cut from
each knee at 200 mm steps and stained with toluidine blue, to
obtain samples of the joint at the center, 200 and 400 mm,
giving coverage over more than half of the joint, including the
central weight-bearing region. Toluidine blue staining was per-
formed on all samples in each study in the same automated-
staining batch to minimize potential differences in technique. The
most central section of the medial femoro-tibial joint (with the
least amount of meniscus) was selected for analysis as the major
weight-bearing region where degradative change was most
profound. Changes in non-calciﬁed cartilage, calciﬁed cartilage and
subchondral bone of the medial tibial plateau (MTP) were scored
0e3 for each parameter by a scorer (SSG) blinded to treatment
group30: 0¼ normal; 1¼mild; 2¼moderate and 3¼ severe path-
ologic degradation to give a total score from 0 to 9. For non-
calciﬁed cartilage: 1¼5e25%; 2¼ 25e50% and 3¼>50% where
the summed breaches of tidemark integrity are expressed as
a percentage of the MTP or medial femoral condyle (MFC) width.
For subchondral bone: 1¼mild; 2¼moderate thinning of the
subchondral bone and increased areas of osteoclastic resorption,
without collapse; 3¼ loss of subchondral bone leading to collapse
of overlying cartilage. Additional scoring was performed at the
central weight-bearing regions on samples obtained 4 days post-
model induction (following only two doses of zoledronate) to
obtain the tidemark erosion %, cartilage thickness and toluidine
blue saturation. The tidemark erosion was measured from 10
images of the MFC and MTP; the length of calciﬁed cartilage
regions that had been resorbed through the tidemark, was sum-
med and divided by the total width of MFC or MTP. The width of
the non-calciﬁed cartilage on the MTP was measured by averaging
three values from the outer, central and inner third regions. Satu-
ration, to reﬂect proteoglycan levels within the cartilage matrix,
was measured by averaging the blue saturation values from the
entire MTP region of manually outlined non-calciﬁed cartilage on
singly-stained toluidine blue sections. All image analyses were
performed with NIS-Element AR 2.30 (Nikon, Avon MA).Osteoclasts were identiﬁed by staining histochemically for
tartrate-resistant acid-phosphatase31,32 following a modiﬁed
version of a previously published method33. Brieﬂy, the sections
were deparafﬁnized, rehydrated, and preincubated in 0.2 M Tris
buffer (pH 9.0, 37 C, 60 min) followed by a further incubation in
Naphthol AS-BI and fast garnet (37 C, 60 min) (Kit 387, Sigma, St
Louis). After washing (distilled water) sections were air dried and
mounted.
Statistical analysis
Behavioral and radiological data were analyzed by a one-way
analysis-of-variance using a customized SAS-Excel applicationwith
treatment as the variable (SAS Institute; Cary, NC). Where a signif-
icant main effect was determined, planned comparisons were
made by least signiﬁcant difference analysis, and the effect of
treatment at each time point was compared to vehicle controls.
Histopathology parameters were analyzed by comparing group
values using ManneWhitney U Test (Prism4, GraphPad Software,
San Diego, CA). Individual P values are reported in the ﬁgure
legends and text and data are presented as mean plus 95% conﬁ-
dence intervals.
Results
MIA results in radiographic changes, loss of BMD and pain
BMD analysis [Fig. 1(A)] revealed a signiﬁcant reduction in BMD
for all three concentrations of MIA 1 week post-injection
(F3,37¼14.94, P< 0.0001). This concentration-dependent effect was
maintained for the 1.0 and 3.0 mg dose 2e4 weeks post-injection. A
coincident and concentration-dependent effect was observed in
weight borne on the affected limb (F3,37¼19.19, P< 0.0001); 3
weeks post-MIA, the 1.0 and 3.0 mg doses caused signiﬁcant deﬁ-
cits [Fig. 1(B)]. In this and later experiments, treatments did not
signiﬁcantly affect body weight. As these animals are actively
growing, it is important to note that it is normal for BMD to increase
Fig. 1. MIA (A, B) reduced BMD and weight borne on the affected limb. Baseline measurements were taken prior to IA administration. Data shown are mean 95% conﬁdence
intervals (n¼ 10 rats/group). Asterisks (*) denote reported P values as compared to sham group, speciﬁcally in graph A, 1 week 0.3 mg P¼ 0.0199, 1 mg P¼ 0.0182, 3 mg P¼ 0.0021;
2 weeks 1 mg P¼ 0.0479, 3 mg P< 0.0001; 3 weeks 1 mg P¼ 0.0084, 3 mg P< 0.0001; 4 weeks 1 mg P¼ 0.0025, 3 mg P< 0.0001. In graph B, 1 mg P¼ 0.0002, 3 mg P< 0.0001.
Radiographic changes (CeD) following MIA in the rat. (C) Radiograph of a rat knee joint from a sham animal. (D) Three weeks following MIA treatment showing osteolysis of the
lateral and femoral condyles (arrows).
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MIA) demonstrated joint degeneration characterized by osteolysis
of the lateral and femoral condyles [Fig. 1(D)] as compared to saline
[Fig. 1(C)], in line with previous descriptions24.
Zoledronate inhibits MIA-induced BMD loss and pain
Pre-emptive chronic zoledronate (10e100 mg/kg) signiﬁcantly
and dose-dependently increased BMD above the level of control
animals, prevented MIA-induced bone loss (F4,44¼172.31,
P< 0.0001) [Fig. 2(A)] and signiﬁcantly and dose-dependently
reversed weight-bearing deﬁcits (F4,44¼ 6.42, P¼ 0.0004) [Fig. 2
(B)]. To determine if zoledronate could reverse established deﬁ-
cits, early sub-chronic treatment was started 2 weeks after model
induction (100 mg/kg, administered on days 14, 17 and 21 only).
Zoledronate signiﬁcantly elevated BMD (F3,59¼143.77, P< 0.0001)
[Fig. 3(A)] and partially, although signiﬁcantly, reversed weight-
bearing deﬁcits (F3,59¼15.28, P< 0.0001) [Fig. 3(B)].
Zoledronate produces partial reversal of BMD loss and pain when
MIA-induced pathology is established
To investigate if zoledronate could affect BMD and weight-
bearing deﬁcits if dosing was further delayed in a model repre-
senting late-stage OA, we initiated dosing (100 mg/kg; every third
day) 2, 3 or 4 weeks post-MIA. Zoledronate signiﬁcantly restored
BMD loss in a time-dependent manner in all treatment groups
(F4,56¼ 44.17, P< 0.0001) [Fig. 4(A)], with the largest effect inanimals dosed the longest. Zoledronate also signiﬁcantly attenu-
ated weight-bearing deﬁcits in all treatment groups (F4,56¼14.60,
P< 0.0001) [Fig. 4(B)]; the largest reversal was observed with early
chronic treatment and the smallest effect with curative sub-chronic
treatment (dosed betweenweeks 4 and 5). To investigate if weight-
bearing deﬁcits were related to joint pain or secondary to insta-
bility, we used the local anesthetic lidocaine. Lidocaine gave partial,
but signiﬁcant, reversal of hind limb weight-bearing deﬁcits
(F2,23¼16.77, P< 0.0001; 42% lidocaine vs 37% vehicle) [Fig. 4(C)];
lidocaine did not affect weight bearing in sham rats.
Zoledronate inhibits cartilage degeneration and histological signs of
joint damage
To understand if the protective effects of zoledronate were via
inhibition of cartilage degeneration, we quantiﬁed joint pathology;
MIA is reported to provide a direct insult to chondrocytes, leading
to severe cartilage damage28,34. Three weeks following MIA, overall
cartilage thinning, loss of chondrocytes, decreased proteoglycan
and areas of total loss of cartilage were observed. Large, multinu-
cleated osteoclasts were present at the boneecartilage interface,
and both subchondral bone and cartilage had been resorbed in the
weight-bearing regions of theMTP [Fig. 5(B)]. Chondrocyte cloning,
indicative of attempted repair, was apparent in the regions
surrounding the areas of cartilage loss, with osteophytes at the joint
periphery, which were more extensive in joints with greater
resorptive pathology. Early sub-chronic zoledronate treatment,
initiated 2 weeks post-MIA [Fig. 5(C)], led to a partial reduction in
Fig. 2. Chronic pre-emptive zoledronate, dose-dependently prevents MIA-induced loss of BMD and weight-bearing deﬁcits. Following chemical (A, B) induction of OA chronic pre-
emptive treatment with zoledronate prevented BMD loss and the reduction of the weight borne on the affected limb. Baseline measurements were taken prior to MIA (1.0 mg)
administration. Data shown are mean 95% conﬁdence intervals (n¼ 10 rats/group). Asterisks (*) denote reported P values as compared to MIA/Veh group, speciﬁcally in graph A, 1
week Sham/Veh P¼ 0.0062, 10 mg/kg P< 0.0001, 30 mg/kg P< 0.0001, 100 mg/kg P< 0.0001; 2 weeks Sham/Veh P¼ 0.0006, 10 mg/kg P< 0.0001, 30 mg/kg P< 0.0001, 100 mg/kg
P< 0.0001; 3 weeks Sham/Veh P¼ 0.0002, 10 mg/kg P< 0.0001, 30 mg/kg P< 0.0001, 100 mg/kg P< 0.0001. In graph B, 1 week Sham/Veh P¼ 0.0044; 2 weeks Sham/Veh P¼ 0.0001,
10 mg/kg P< 0.0451, 30 mg/kg P< 0.0095, 100 mg/kg P< 0.0059; 3 weeks Sham/Veh P< 0.0001, 10 mg/kg P< 0.0454, 30 mg/kg P< 0.0286, 100 mg/kg P< 0.0001.
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subchondral bone. In contrast, pre-emptive chronic zoledronate
[Fig. 5(D)] resulted in a preservation of the joint, such that images
were indistinguishable from control. Quantiﬁcation of these
histological ﬁndings [Fig. 5(E)] demonstrated that erosion of bone
and cartilage was signiﬁcantly reduced with early sub-chronic
zoledronate and was prevented by pre-emptive chronic treatment,
such that the pathology and score were not signiﬁcantly different
from controls.
To further characterize the role of subchondral bone in joint
destruction, we investigated an early time point (4 days post-
MIA). As expected, the bone and cartilage changes were less
severe than that seen at 3 weeks, and the articular surfaces and
joint architecture were largely intact [Fig. 6(AeF)]. Evaluation of
the synovium showed a normal one-cell thick synovial intima in
the saline-injected knees, and few cells in the underlying loose
connective tissue. Signiﬁcant synovitis occurred in all MIA animals
(both controls and zoledronate-treated) with intimal hyperplasia
(2e4 cells thick), subintimal ﬁbrosis and moderate diffuse
inﬂammatory cell inﬁltrates [Fig. 6(A)]. Slight (non-signiﬁcant)
thinning of the cartilage was present with MIA treatment. AFig. 3. Delayed treatment with zoledronate inhibits MIA-induced loss of BMD and weight-
zoledronate prevents BMD loss and the reduction of the weight borne on the affected limb. B
mean 95% conﬁdence intervals (n¼ 10 rats/group). Asterisks (*) denote reported P values
MIA/Zol (Pre-emptive Chronic) P< 0.0001; 2 weeks Sham/Veh P¼ 0.0465, MIA/Zol (Pre-emp
P< 0.0001, MIA/Zol (Early Sub-Chronic) P< 0.0001. In graph B, 1 week Sham/Veh P< 0.00
(Pre-emptive Chronic) P¼ 0.0008; 3 weeks Sham/Veh P< 0.0001, MIA/Zol (Pre-emptive Chdecrease in toluidine blue staining, indicating a loss of proteo-
glycan, was observed with mean saturation values; saline 104 2;
MIA 86 4; MIAþ zoledronate 89 4. In contrast, intense stain-
ing of the proximal tibial growth plate was consistent across the
groups (Supplementary Figure 4). Large, multinucleated osteo-
clasts adjacent to the calciﬁed cartilage were prominent in these
actively growing animals, likely representing natural remodeling.
A greater level of osteoclastic activity was observed in the MIA
group, with resorption of the calciﬁed cartilage up-to and beyond
the tidemark (the line separating the calciﬁed and non-calciﬁed
cartilage) and evidence of additional erosion of the non-calciﬁed
cartilage [Figs. 6(B, E) and 7]. Chondrocytes were viable across all
regions of the joint surface. Focal loss of proteoglycan, with or
without necrosis and loss of chondrocytes, were observed in
regions where tidemark integrity was breached. Zoledronate
protected toluidine blue staining and cartilage integrity [Fig. 6(C,
F)] without affecting synovitis. Quantiﬁcation of these histological
ﬁndings demonstrated that erosion of bone, cartilage [Fig. 6(G)]
and tidemark [Fig. 6(H)] was signiﬁcantly increased with MIA
treatment, which was signiﬁcantly reduced by two doses of
zoledronate.bearing deﬁcits. Two weeks following chemical (A, B) induction of OA, treatment with
aseline measurements were taken prior to MIA (1.0 mg) administration. Data shown are
as compared to MIA/Veh group, speciﬁcally in graph A, 1 week Sham/Veh P¼ 0.0026,
tive Chronic) P< 0.0001; 3 weeks Sham/Veh P¼ 0.0178, MIA/Zol (Pre-emptive Chronic)
01, MIA/Zol (Pre-emptive Chronic) P¼ 0.0154, 2 weeks Sham/Veh P< 0.0001, MIA/Zol
ronic) P¼ 0.0007, MIA/Zol (Early Sub-Chronic) P¼ 0.022.
Fig. 4. Zoledronate, administered to animals at advanced stages of joint degeneration, partially inhibits MIA-induced loss of BMD (A) and weight-bearing deﬁcits (B). Baseline
measurements were taken prior to IA administration. Data shown are mean 95% conﬁdence intervals (n¼ 10 rats/group). Asterisks (*) denote signiﬁcance (P< 0.05) fromMIA/Veh
group. Effect of IA lidocaine on weight bearing following MIA (C). Baseline measurements were taken prior to MIA (1.0 mg) administration. Data shown are mean 95% conﬁdence
intervals (n¼ 10 rats/group). Asterisks (*) denote reported P values as compared to MIA/Veh group, speciﬁcally in graph A, 1 week Sham/Veh P< 0.0001; 2 weeks Sham/Veh
P¼ 0.0033; 3 weeks Sham/Veh P< 0.0001, MIA/Zol (Early Chronic) P< 0.0001; 4 weeks Sham/Veh P< 0.0001, MIA/Zol (Early Chronic) P< 0.0001, MIA/Zol (Delayed Chronic)
P< 0.0001, MIA/Zol (Curative Sub-Chronic) P¼ 0.0030. 5 weeks Sham/Veh P< 0.0001, MIA/Zol (Early Chronic) P< 0.0001, MIA/Zol (Delayed Chronic) P< 0.0001, MIA/Zol (Curative
Sub-Chronic) P< 0.0001. In graph B, Sham/Veh P< 0.0001, MIA/Zol (Early Chronic) P< 0.0001, MIA/Zol (Delayed Chronic) P¼ 0.0005, MIA/Zol (Curative Sub-Chronic) P¼ 0.0118.
In graph C, MIA/2% Lidocaine P¼ 0.0134.
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Increased bone remodeling is a frequent ﬁnding in scintigraphy
studies of OA joints, and controversy exists whether OA changes
commence in cartilage or bone35,36. As such, subchondral bone
turnover has attracted attention20, with antiresorptives, such as
bisphosphonates, representing potentially disease-modifying
therapies. While data from animals have been encouraging17e19,
clinical trials have yielded mixed and overall disappointing
results1,2,20,21,22,37. We hypothesized that the stage of disease when
antiresorptive therapies are employed may contribute to this
disconnect. Previous preclinical studies have used chronic dosingFig. 5. Zoledronate prevents MIA-induced cartilage degeneration. Representative histology
loss of cartilage was noted in MIA treated joints (B), as compared to control joints (A). Early s
both toluidine blue staining and cartilage integrity. Pre-emptive chronic treatment with z
indistinguishable from control sections. Quantiﬁed severity scores showing reduction of jo
conﬁdence intervals (n¼ 3 rats/group). Asterisks (*) denote reported P values as compared t
Pound sign (#) denotes reported P value as compared to MIA/Veh group, speciﬁcally MIA/Zthat was initiated pre-emptively, while clinical trials have used
patient populations with existing, heterogeneous, and in some
cases advanced, disease. To date, the relationship between disease
severity and bisphosphonate efﬁcacy has not been addressed pre-
clinically. We therefore utilized the MIA model of painful joint
degeneration in young rats, combining zoledronate treatment
initiated at varying times after model induction with a correlative
analysis of structural changes and pain. We conﬁrmed our radio-
graphical and behavioral results in a second surgically induced
model. These two models vary most notable in severity; the MIA
model induces substantial inﬂammation in the soft tissues, espe-
cially at early time points and progresses until severe widespreadimages of toluidine blue stained sections 3 weeks following MIA (1.0 mg). A profound
ub-chronic zoledronate treatment when initiated 2 weeks after MIA (C), reduced loss of
oledronate (D) resulted in a near complete saving of the joint such that images were
int degeneration as a result of zoledronate treatment (E). Data shown are mean 95%
o sham group, speciﬁcally MIA/Veh P< 0.0001, MIA/Zol (Early Sub-Chronic) P¼ 0.0109.
ol (Early Sub-Chronic) P¼ 0.0010, MIA/Zol (Pre-emptive Chronic) P< 0.0001.
Fig. 6. Zoledronate prevents MIA-induced osteoclastic resorption of calciﬁed cartilage. Representative histology images of toluidine blue stained sections 4 days following saline (A
and D), MIA (B and E) knee injection and following MIA (1.0 mg) knee injection receiving two doses of zoledronate (C and F). Prominent synovitis was present with MIA treatment (B
and C, black arrows) and the toluidine blue proteoglycan staining was decreased. Viable chondrocytes, including at the superﬁcial layers, were present in the cartilage matrix.
Chondrocyte and severe proteoglycan loss was only appreciable in focal areas adjacent to osteoclast resorption of the calciﬁed cartilage (E, white arrows). Zoledronate treatment
reduced the resorption of the calciﬁed cartilage to preserve tidemark integrity. Quantiﬁed severity scores showing statistically signiﬁcant joint degeneration (G) and tidemark
erosion (H) as a result of MIA, with a statistically signiﬁcant reduction when treated with zoledronate. Data shown are mean 95% conﬁdence intervals (n¼ 5 rats/group). Asterisks
(*) denote reported P values as compared to sham group, speciﬁcally in graph G, MIA/Veh P< 0.0001, MIA/Zol P¼ 0.0011. In graph H MIA/Veh P< 0.0001. Pound sign (#) denotes
reported P value as compared to MIA/Veh, speciﬁcally in graph G MIA/Zol P¼ 0.007. In graph H MIA/Zol P< 0.0001.
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has been criticized as not being fully representative of human
disease. In contrast, the medial meniscal tear (MMT) model induces
substantially less soft tissue inﬂammation and progresses to
a small, focused, but often complete cartilage injury. The main
conclusions from our study are that early and aggressive zoledro-
nate treatment increases BMD, prevents cartilage degeneration and
inhibits pain. Zoledronate also increased BMD and reversed pain in
animals with advanced disease with a reduced magnitude of effect.
Importantly, at early time points, we show osteoclast-mediated
cartilage resorption that was inhibited by zoledronate.
Our ﬁndings are in line with previous preclinical studies17e19;
Hayami and colleagues18, investigated alendronate in a rat OA
model induced by transection of the ACL. Alendronate, adminis-
tered 3 days prior to surgery and twice weekly thereafter, inhibited
bone resorption and was chondroprotective. In the current study,
we also extended our radiographic and behavioral analysis to
include the medial meniscal tear OA model30 and show that
surgery-induced BMD loss and pain are also prevented by zoledr-
onate. Taken together, these ﬁndings demonstrate that subchondral
bone remodeling is important in the pathogenesis of OA in these
model systems. The current study also suggests that subchondralbone remodeling may be most relevant and amenable to inter-
vention at early time points. Our study is the ﬁrst to report the
effects of a bisphosphonate on pain as a functional readout in
preclinical OA models. Despite the recognized discord between
articular damage and pain38, we anticipated that by preserving
joint structural integrity, pain reduction would result; however, we
were, surprised by the near complete prevention of joint degen-
eration and the magnitude of pain inhibition afforded by pre-
emptive chronic zoledronate. We also did not anticipate that
zoledronate would result in pain reduction when administered to
animals with advanced joint degeneration, although this ﬁnding is
in line with clinical data showing bisphosphonate-mediated pain
reduction in the absence of measurable effects on joint
structure1,20,22.
We postulate three potential mechanisms by which
bisphosphonates could reduce joint damage and pain in these
models. First, as MIA is a glycolysis inhibitor and thought to be
selectively toxic to chondrocytes due to their dependence on this
energy pathway39, zoledronate may directly inhibit MIA-induced
chondrocyte cell death, thereby preserving joint integrity and
reducing pain. Indeed, bisphosphonates have been shown to have
direct effects on cartilage19; however, beyond 2 weeks post-MIA
Fig. 7. Tartrate-resistant acid-phosphatase staining technique used to identify osteoclasts and their role during the pathological change following IA injection of MIA (B) as
compared to IA saline (A). After injection, MIA increased osteoclastic number and activity in both subchondral bone surface and metaphyseal trabecular surface. CART, cartilage
layer; SB, subchrondral bone layer.
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this mechanism is unlikely.
A second mechanism implicates osteoclasts in directly killing
chondrocytes and/or actively breaking down cartilage. In a scenario
where MIA injures, rather than kills chondrocytes; their ultimate
demise requires signals originating from osteoclasts. This is
consistent with our observation of viable chondrocytes at early
time points, including at the peripheral cartilage, in line with
previous reports43. At early time points post-MIA cell and proteo-
glycan loss was only observed in close proximity to areas of oste-
oclast-mediated cartilage resorption. These preclinical ﬁndings are
consistent with a recent clinical study demonstrating that cartilage
loss occurs in the same regions as subchondral bone attrition13.
Inhibiting osteoclasts therefore would be chondroprotective and
prevent cartilage resorption. This mechanism could explain both
the effect of pre-emptive chronic dosing and when dosing was
delayed for 2 weeks; however, at 4 weeks post-MIA, cartilage
damage was severe, likely rendering cartilage-sparing therapies
less relevant.
The third mechanism involves a direct analgesic action of
zoledronate via the central and/or peripheral nervous system and
may explain efﬁcacy when dosed at late time points. Zoledronate is
analgesic when present in the plasma; however, this is unlikely to
affect our studies, as behavioral testing was conducted on days
when pharmacologically relevant circulating levels were not
present (behavior and dosing conducted on separate days). We also
have previously demonstrated that chronic zoledronate does not
affect pain thresholds in control animals when dosing and testing
days are separated29. Alternatively, as bone is heavily innervated29,
cartilage and trabecular bone degeneration may result in exposure
of sensory nerve terminals to chemical or mechanical stimulation
not present in normal joints. Bisphosphonate-induced increases in
BMD may help to protect these exposed nerve ﬁbers, shielding
them from excitatory stimuli. We found that IA lidocaine inhibited
pain from the MIA injected joint without effect on sham. While it is
unknown whether weight-bearing deﬁcits in OA models represent
pain or instability, lidocaine blockade suggests at least a component
is due to nociception. It is noteworthy that even with pre-emptive
chronic pre-emptive bisphosphonate treatment weight bearing
was not reversed to the level of sham controls; the residual deﬁcit
may represent instability. Alternatively, the deﬁcit may constitute
a learned behavior with more time required for resolution. Pain-
producing stimuli may originate from the injured chondrocytes orthe soft tissues; however, at early time points, bisphosphonates did
not have an observable effect on the histological signs of inﬂam-
mation in the synovium or soft tissues. Excitatory stimuli may also
come from the subchondral bone; osteoclasts remodel bone in
a low pH environment and sensory nerve ﬁbers contain acid-
sensitive ion channels that when activated produce pain. Further-
more, osteoclasts are implicated in Freund’s adjuvant-induced
chronic inﬂammatory pain, with bisphosphonates reducing pain
and spinal c-Fos activation44. This theory is also supported by the
recent ﬁnding that mice deﬁcient for type IX collagen have
enlarged osteoclasts, reduced trabecular bone and increased pain
sensitivity45,46 and also by data showing a correlation between
exposure of the subchondral bone plate and pain in OA patients14.
Hence, increased osteoclastic activity, as found in OA, could
contribute to neuronal excitation and pain, and so inhibition of
osteoclasts would be analgesic.
Our ﬁndings show that osteoclast-mediated resorption of
cartilage at the subchondral boneecartilage interface is an early
initiating event in the pathobiology of theMIAmodel as opposed to
chondrocyte death and subsequent mechanical erosion of the
articular surface. Importantly, the resorption observed in the
current study occurred in the central weight-bearing areas of
the joint, a site distinctly different from inﬂammation-related
resorption which occurs at the joint margin. We speculate this
requires communication between bone cells and chondrocytes
across the tidemark and calciﬁed cartilage. Such boneecartilage
communication has been described during longitudinal bone
growth, where osteoclasts break down cartilage at the epiphyseal
growth plates39. Furthermore, bisphosphonates impair bone
growth during development47 and delay removal of endochondral
cartilaginous matrix following distraction48, consistent with oste-
oclast-mediated resorption of cartilage.
In conclusion, we have demonstrated that pre-emptive chronic
bisphosphonate treatment increases BMD and is both chon-
droprotective and analgesic in the MIA (and MMT) models of
painful joint degeneration in the rat. Bisphosphonates partially
protect joints and alleviate pain when treatment is delayed up to 2
weeks. When joint degeneration is advanced, bisphosphonates
alleviate pain with reduced efﬁcacy. These ﬁndings may help
explain the disconnect between the effects of bisphosphonates
clinically vs pre-clinically. Although speculative, should these
ﬁndings translate clinically, they suggest that early and aggressive
bisphosphonate treatment may lead to improved outcomes. Such
B.W. Strassle et al. / Osteoarthritis and Cartilage 18 (2010) 1319e1328 1327a treatment regime may be best suited to trauma-induced OA, in
particular, the common cartilage and ligament injuries associated
with sports, where treatment can be initiated soon after injury.
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